A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Brown, Jennifer R
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. [electronic resource] - British journal of haematology Jun 2009 - 741-8 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
1365-2141
10.1111/j.1365-2141.2009.07677.x doi
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymphoma--drug therapy
Lymphoma, B-Cell, Marginal Zone--drug therapy
Lymphoproliferative Disorders--drug therapy
Male
Middle Aged
Prospective Studies
Rituximab
Survival Rate
Vidarabine--adverse effects
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. [electronic resource] - British journal of haematology Jun 2009 - 741-8 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
1365-2141
10.1111/j.1365-2141.2009.07677.x doi
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymphoma--drug therapy
Lymphoma, B-Cell, Marginal Zone--drug therapy
Lymphoproliferative Disorders--drug therapy
Male
Middle Aged
Prospective Studies
Rituximab
Survival Rate
Vidarabine--adverse effects